In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986 Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center, a position he held until 2009.He is currently Distinguished Professor, Univ. of Colorado and James Dudley endowed Professor at the University. Dr. Bunn has been President of ASCO, IASLC, and AACI, chairman of the FDA Oncology Drug Advisory Committee.
Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct lung cancer translational research and Principal Investigator for the Lung Cancer Mutation Consortium.
Dr. deVere White is associate dean for cancer programs at UC Davis School of Medicine, director of the UC Davis Comprehensive Cancer Center and a professor of urology. He received his medical degree from Dublin University in Dublin, Ireland, and completed an internship and residencies in surgery and urology at St. Vincent’s Hospital in Dublin and at Duke University Medical Center.
His expertise resides in prostate and bladder cancers including: patient care, targeted therapies, diagnostics and biomelecular mechanisms that make certain prostate cancers more virulent than others. Dr. deVere White serves on the editorial boards of six international scientific journals and, has authored over 300 peer-reviewed scientific articles and book chapters.
He is a past president of the Society of Urologic Oncology, a member of the Clinical Society of Genitourinary Surgeons and an elected member of the prestigious American Association of Genitourinary Surgeons. He has been named multiple times as one of “The Best Doctors in America.”
John N. Galgiani was born in San Francisco, received his BA from Stanford University, his MD from Northwestern University, and a fellowship in Infectious Diseases from Stanford. In 1978, Dr. Galgiani joined the faculty of the University of Arizona and currently he is Professor of Medicine. Dr. Galgiani has focused his career primarily on the special problems of coccidioidomycosis (Valley Fever) and its impact on the general population and special groups such as organ transplant recipients and patients with AIDS. For 19 years, he was project director of an NIH-sponsored coccidioidomycosis clinical trials group. Dr. Galgiani’s laboratory has collaborated in efforts to develop vaccines to prevent Valley Fever. For the past 8 years, Dr. Galgiani has led a development program for nikkomycin Z, a possible cure for Valley Fever, now in clinical trials. In 1996, Dr. Galgiani founded the Valley Fever Center for Excellence to disseminate information about Valley Fever, help patients with the severest complications of this disease, and to encourage research into the biology and diseases of its etiologic agent.
Dr. Putterman is Professor of Medicine and Microbiology & Immunology, and Chief of the Division of Rheumatology at the Albert Einstein College of Medicine and Montefiore Medical Center (Bronx, New York). Dr. Putterman’s major research interests are in the field of immunology and autoimmune diseases, and specifically the identification and characterization of novel mechanisms, biomarkers, and treatment approaches to inflammatory arthritis and systemic lupus erythematosus. Dr. Putterman’s laboratory has received funding from the National Institute of Health, Alliance for Lupus Research, Lupus Research Institute, Arthritis Foundation, and Biogen Idec, and he has published more than 160 articles and book chapters in the medical and scientific literature. He was elected to the American Society of Clinical Investigation, and is a member of the American College of Rheumatology and the American Association of Immunologists. Dr. Putterman has served on multiple NIH and international study sections, and is currently a member of several editorial boards.
Betty Diamond, M.D. is a leading expert and researcher of autoimmune disease. She is currently the head of the Center for Autoimmune and Musculoskeletal Diseases at The Feinstein Institute for Medical Research and, Director of the MD/PhD and PhD programs at the Hofstra North Shore-LIJ School of Medicine.
Diamond’s primary interests are in the mechanisms of central and peripheral tolerance of autoreactive B-Cells. Her leadership in lupus led to the discovery of the first idiotype marker on anti-DNA antibodies in patients with lupus, and she discovered anti-DNA antibodies in patients and mice shared characteristics with antibodies to pneumococcal polysaccharide. Her breakthroughs have resulted in Honors and Awards from the Lupus Foundation, ACR, Arthritis Foundation and many others. She has served in leadership positions in: American Association of Immunology, American College of Rheumatology and, the Scientific Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
A graduate of Harvard University earning both a BA and MD, she performed a residency in internal medicine at Columbia Presbyterian Medical Center and received postdoctoral training in immunology at the Albert Einstein College of Medicine.
Dr. Robinson joins the HealthTell Advisory Team with significant experience as a researcher, professor and clinician.
His Laboratory studies the molecular mechanisms that drive rheumatoid arthritis, multiple sclerosis, and osteoarthritis. In 2011, his laboratory published seminal findings demonstrating a key role for low-grade inflammation, and not just “wear and tear” in the pathogenesis of osteoarthritis. Dr. Robinson’s research team found that the human body produces inflammatory proteins, which can be emitted for years after an injury, which accelerates the development of arthritis.
Dr. Robinson graduated from the Stanford University School of Medicine. He currently serves as an Associate Professor of Medicine-Immunology & Rheumatology at Stanford, and is a board-certified and practicing Rheumatologist. He’s also a member of the Stanford Cancer Institute and the Stanford Institute for Immunity Transplantation and Infection (ITI), and is an elected member of the American Society of Clinical Investigation (ASCI).
Dr. David Nemazee is ideally suited to join the HealthTell Advisory Team as an expert in B-cell immunology. He currently serves as a professor in the Department of Immunology and Microbial Science at The Scripps Research Institute. Specifically, his research is focused on antibodies and their relationship to autoimmune diseases. For roughly 15 years, he has been researching antibodies and why they sometimes attack healthy cells in the body, leading to autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
Before joining The Scripps Research Institute, Dr. Nemazee served as a faculty member at the National Jewish Center for Immunology and Respiratory Medicine in Denver, Colo. He also worked at the Basel Institute for Immunology in Basel, Switzerland. Dr. Nemazee earned his undergraduate, master’s, and Ph.D. degrees from Harvard University. He has received several awards for his research, is a prolific writer of research papers, has coordinated a variety of scientific conferences, and serves as a reviewer of a number of professional journals.